Protagonist Therapeutics (PTGX) Return on Invested Capital (2018 - 2024)

Protagonist Therapeutics (PTGX) has 6 years of Return on Invested Capital data on file, last reported at 76.48% in Q1 2024.

• For the quarter ending Q1 2024, Return on Invested Capital changed N/A year-over-year to 76.48%; the trailing twelve-month figure through Mar 2024 stood at 76.48% (changed N/A YoY), and the FY2020 full-year result was 0.1%, up 4.0% from the prior year.
• Return on Invested Capital rose to 76.48% in Q1 2024, from 11.13% in the prior quarter.
• In the past five years, Return on Invested Capital ranged from a high of 76.48% in Q1 2024 to a low of 11.13% in Q4 2023.
• A 4-year average of 9.31% and a median of 0.03% in 2020 frame the typical range for Return on Invested Capital.
• Across the five-year window, Return on Invested Capital gained 16 bps in 2020 and changed 0 bps in 2021, its largest moves.
• Tracing PTGX's Return on Invested Capital over 4 years: stood at 0.03% in 2020, then tumbled by 45 bps to 0.05% in 2021, then sank by 22526 bps to 11.13% in 2023, then surged by 787 bps to 76.48% in 2024.
• Business Quant data shows PTGX's Return on Invested Capital at 76.48% in Q1 2024, 11.13% in Q4 2023, and 0.05% in Q1 2021.